| Product Code: ETC13221809 | Publication Date: Apr 2025 | Updated Date: Aug 2026 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Bhawna Singh | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
| Market Size (2025) | USD 3.8 Billion |
| Forecast Size (2032) | USD 6.5 Billion |
| CAGR | 7.88% |
| Base Year | 2025 |
| Forecast Period | 2026-2032 |
| Largest Region | North America |
| Fastest Growing Region | Asia Pacific |
| Largest Segment | Minimally Invasive Devices |
| Fastest Growing Segment | Implantable Devices |
| Leading Companies | Urotronic, Inc., Olympus Corporation, Boston Scientific Corporation, KARL STORZ SE & Co. KG, Urologix, LLC. |

The Global Benign Prostatic Hyperplasia Devices Market was estimated at USD 3.8 Billion in 2025 and is projected to reach USD 6.5 Billion by 2032, growing at a CAGR of 7.88% from 2026 to 2032.
The Global Benign Prostatic Hyperplasia Devices Market is experiencing a notable shift as the prevalence of BPH escalates among aging male populations worldwide. This demographic trend is propelling the demand for advanced medical devices tailored to alleviate symptoms such as urinary retention and frequent urination. The market's expansion is further fueled by technological innovations that enhance the efficacy and safety of BPH treatments, positioning the sector for sustained growth in the coming years.
The market's trajectory is also influenced by the increasing adoption of minimally invasive procedures, which offer patients quicker recovery times and reduced risk of complications. This shift is prompting healthcare providers to invest in state-of-the-art devices that align with evolving treatment protocols and patient preferences, thereby driving the market's growth and transformation.
This graph illustrates the annual growth rates of the Global Benign Prostatic Hyperplasia Devices Market from 2022 to 2032, highlighting a steady upward trajectory and projected expansion over the forecast period.

The table below presents the year‑wise growth rates along with the key drivers influencing the market
| Year | Growth Rate (%) | Major Drivers |
| 2022 | 9.31 | Hospitals are expanding their offerings of benign prostatic hyperplasia devices across regions. |
| 2023 | 5.69 | Patients experience rising out-of-pocket costs for benign prostatic hyperplasia devices, affecting utilization. |
| 2024 | 11.59 | Pharmacies are increasing their stock of benign prostatic hyperplasia devices in response to patient demands. |
| 2025 | 6.41 | Changing patient preferences for non-invasive treatments contribute to greater benign prostatic hyperplasia device adoption. |
| 2026 | 8.72 | Supply chain improvements in the distribution of benign prostatic hyperplasia devices enhance accessibility. |
| 2027 | 7.57 | Within the North American market, benign prostatic hyperplasia devices see intensified competition among manufacturers. |
| 2028 | 9.5 | While investment in digital therapeutics accelerates, benign prostatic hyperplasia device innovation follows suit. |
| 2029 | 6.24 | A tightening labor market is leading to scarcity in skilled professionals for benign prostatic hyperplasia procedures. |
| 2030 | 9.52 | A shift toward advanced biosensor technology changes the capabilities of benign prostatic hyperplasia devices. |
| 2031 | 7.02 | Wearable monitoring devices are becoming crucial for managing benign prostatic hyperplasia patient outcomes sustainably. |
| 2032 | 7.27 | New FDA regulations prompt enhancements in the safety standards for benign prostatic hyperplasia devices. |
Note - Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary research methodology, combining internal industry data, secondary research, and primary validation, updated periodically to reflect current market conditions. As markets evolve rapidly, figures for certain industries may vary slightly and are intended as informed estimates rather than absolute figures. For the most current market sizing, we recommend validating figures with a 6Wresearch analyst.
Below are some of the specific key takeaways from the market, including:
The Global Benign Prostatic Hyperplasia Devices Market faces several challenges that could impede its growth. Regulatory hurdles, such as the stringent requirements outlined in 21 CFR § 876.5510 for temporarily-placed urethral opening systems, can delay the introduction of new devices. For example, the FDA mandates comprehensive clinical performance testing to evaluate improvements in urinary outflow symptoms and document adverse events, which can be time-consuming and costly. Additionally, the high costs associated with advanced medical devices may limit their adoption in emerging markets, where budget constraints are more pronounced. Moreover, the presence of alternative treatment options, including pharmacological therapies and traditional surgical procedures, offers patients a range of choices, potentially affecting the market share of device-based treatments. These factors necessitate strategic planning and innovation to navigate the competitive landscape effectively.
The Global Benign Prostatic Hyperplasia Devices Market is witnessing several notable trends that are shaping its future direction. One significant trend is the integration of advanced technologies into treatment devices. For instance, the FDA's approval of the Optilume BPH Catheter System on June 30, 2023, introduced a drug-coated balloon catheter system designed to treat enlarged prostates, highlighting a move towards more effective and less invasive treatment options. Another trend is the inclusion of the iTind procedure in the American Urological Association's clinical practice guideline in September 2023, reflecting a growing acceptance of temporary implantable devices for managing lower urinary tract symptoms associated with BPH. These developments indicate a shift towards treatments that offer patients quicker recovery times and reduced risk of complications, aligning with the broader movement towards minimally invasive procedures in the healthcare sector.
The Global Benign Prostatic Hyperplasia Devices Market presents several opportunities for growth and innovation. The approval of the Optilume BPH Catheter System by Urotronic, Inc. in June 2023 opens avenues for expanding the market presence of drug-coated balloon catheter systems, catering to the demand for less invasive treatment options. Additionally, the inclusion of the iTind procedure in the American Urological Association's guidelines in September 2023 indicates a growing acceptance of temporary implantable devices, presenting opportunities for companies to develop and market such devices. Furthermore, the increasing prevalence of BPH among aging populations worldwide creates a sustained demand for effective treatment solutions, encouraging investment in research and development to meet this need. These factors collectively contribute to a dynamic and evolving market landscape, ripe for strategic initiatives and innovation.
In the Global Benign Prostatic Hyperplasia Devices Market, the Transurethral Resection of the Prostate (TURP) procedure leads with a share of approximately 41.83% in 2025. This dominance is attributed to TURP's established efficacy and widespread acceptance as a standard treatment for BPH. However, the Implantable Devices segment is the fastest-growing, with a projected Compound Annual Growth Rate (CAGR) of 9.1% from 2024 to 2030. This growth is driven by the increasing preference for minimally invasive procedures that offer quicker recovery times and reduced risk of complications. The adoption of implantable devices such as UroLift and iTind is expanding, particularly in outpatient settings, as they provide effective symptom relief with fewer side effects compared to traditional surgical methods.
Among end users in the Global Benign Prostatic Hyperplasia Devices Market, hospitals hold the largest share, accounting for approximately 58.72% in 2025. This dominance is due to hospitals' capacity to handle complex cases and provide comprehensive care. However, Ambulatory Surgical Centers (ASCs) are the fastest-growing segment, with a projected Compound Annual Growth Rate (CAGR) of 9.62% from 2026 to 2031. This growth is attributed to the increasing preference for outpatient procedures, which offer cost-effective and efficient treatment options for patients. The shift towards ASCs is also supported by favorable reimbursement policies and the growing adoption of minimally invasive techniques that align with outpatient care models.
Regionally, North America leads the Global Benign Prostatic Hyperplasia Devices Market, accounting for approximately 36.85% of the market share in 2025. This dominance is driven by advanced healthcare infrastructure, high adoption rates of new medical technologies, and a significant aging population. The Asia Pacific region is the fastest-growing, with a projected Compound Annual Growth Rate (CAGR) of 8.08% from 2026 to 2031. This growth is fueled by increasing healthcare investments, rising awareness of BPH treatments, and a rapidly aging population in countries like Japan, China, and India. The expansion of healthcare facilities and the adoption of advanced medical devices in these countries contribute to the market's rapid growth in the region.
The regulatory landscape for the Global Benign Prostatic Hyperplasia Devices Market is shaped by various government initiatives aimed at ensuring device safety, efficacy, and accessibility. These initiatives encompass regulatory approvals, clinical guidelines, and reimbursement policies that influence market dynamics and growth trajectories.
The Global Benign Prostatic Hyperplasia Devices Market is expected to undergo transformative shifts driven by advancements in device technology and an evolving healthcare landscape. As regulatory bodies like the FDA streamline approval processes, firms will likely accelerate the introduction of next-generation devices, enhancing treatment options. The rise in outpatient procedures aligns with the need for cost-effective solutions, compelling healthcare providers to invest in innovative treatment modalities. Companies like Urotronic, with its recent FDA-approved Optilume BPH Catheter System, are setting new standards, emphasizing minimally invasive approaches that improve patient outcomes.
Recent developments in the Global Benign Prostatic Hyperplasia Devices Market highlight significant advancements that can reshape competitive dynamics and treatment accessibility.
The Global Benign Prostatic Hyperplasia Devices Market is characterized by a competitive landscape that features both established firms and emerging players. While a handful of companies dominate the market, the presence of niche firms with specialized technologies continues to enrich innovation and service diversification.
| Leading Company | Core Strength | Strategic Focus |
|---|---|---|
| Urotronic, Inc. | Pioneering minimally invasive techniques | Expansion in the outpatient device segment |
| Olympus Corporation | Advanced endoscopic equipment | Enhancing image quality for surgical procedures |
| Boston Scientific Corporation | Comprehensive urology portfolio | Innovative clinical partnerships to improve patient outcomes |
| KARL STORZ SE & Co. KG | Expertise in surgical visualization technologies | Development of integrated surgical solutions |
| Urologix, LLC. | Specialized in thermal therapies | Investment in clinical research for long-term therapies |
The distinctive capabilities of these key players not only set them apart in terms of technological advancements but also define their strategic trajectories, influencing the market's evolution as they respond to the growing demand for effective BPH treatments.
Global Benign Prostatic Hyperplasia Devices Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Benign Prostatic Hyperplasia Devices Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Benign Prostatic Hyperplasia Devices Market Revenues & Volume, 2022 & 2032F |
3.3 Global Benign Prostatic Hyperplasia Devices Market - Industry Life Cycle |
3.4 Global Benign Prostatic Hyperplasia Devices Market - Porter's Five Forces |
3.5 Global Benign Prostatic Hyperplasia Devices Market Revenues & Volume Share, By Regions, 2022 & 2032F |
3.6 Global Benign Prostatic Hyperplasia Devices Market Revenues & Volume Share, By Procedure Type, 2022 & 2032F |
3.7 Global Benign Prostatic Hyperplasia Devices Market Revenues & Volume Share, By End User, 2022 & 2032F |
4 Global Benign Prostatic Hyperplasia Devices Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Benign Prostatic Hyperplasia Devices Market Trends |
6 Global Benign Prostatic Hyperplasia Devices Market, 2022-2032 |
6.1 Global Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By Procedure Type, 2022-2032 |
6.1.1 Overview & Analysis |
6.1.2 Global Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By Transurethral Resection of the Prostate (TURP), 2022-2032 |
6.1.3 Global Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By Prostatic Urethral Lift (PUL), 2022-2032 |
6.1.4 Global Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By Prostatectomy, 2022-2032 |
6.1.5 Global Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By Laser Surgery, 2022-2032 |
6.1.6 Global Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By Transurethral Microwave Therapy (TUMT), 2022-2032 |
6.1.7 Global Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By Transurethral Needle Ablation of the Prostate (TUNA), 2022-2032 |
6.1.8 Global Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By Prostatic Stenting/Implants, 2022-2032 |
6.1.9 Global Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By Others, 2022-2032 |
6.2 Global Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By End User, 2022-2032 |
6.2.1 Overview & Analysis |
6.2.2 Global Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By Hospitals and Clinics, 2022-2032 |
6.2.3 Global Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By Ambulatory Surgical Centers, 2022-2032 |
6.2.4 Global Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By Others, 2022-2032 |
6.3.1 Overview & Analysis |
7 North America Benign Prostatic Hyperplasia Devices Market, Overview & Analysis |
7.1 North America Benign Prostatic Hyperplasia Devices Market Revenues & Volume, 2022-2032 |
7.2 North America Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By Countries, 2022-2032 |
7.2.1 United States (US) Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, 2022-2032 |
7.2.2 Canada Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, 2022-2032 |
7.2.3 Rest of North America Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, 2022-2032 |
7.3 North America Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By Procedure Type, 2022-2032 |
7.4 North America Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By End User, 2022-2032 |
8 Latin America (LATAM) Benign Prostatic Hyperplasia Devices Market, Overview & Analysis |
8.1 Latin America (LATAM) Benign Prostatic Hyperplasia Devices Market Revenues & Volume, 2022-2032 |
8.2 Latin America (LATAM) Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By Countries, 2022-2032 |
8.2.1 Brazil Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, 2022-2032 |
8.2.2 Mexico Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, 2022-2032 |
8.2.3 Argentina Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, 2022-2032 |
8.2.4 Rest of LATAM Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, 2022-2032 |
8.3 Latin America (LATAM) Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By Procedure Type, 2022-2032 |
8.4 Latin America (LATAM) Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By End User, 2022-2032 |
9 Asia Benign Prostatic Hyperplasia Devices Market, Overview & Analysis |
9.1 Asia Benign Prostatic Hyperplasia Devices Market Revenues & Volume, 2022-2032 |
9.2 Asia Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By Countries, 2022-2032 |
9.2.1 India Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, 2022-2032 |
9.2.2 China Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, 2022-2032 |
9.2.3 Japan Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, 2022-2032 |
9.2.4 Rest of Asia Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, 2022-2032 |
9.3 Asia Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By Procedure Type, 2022-2032 |
9.4 Asia Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By End User, 2022-2032 |
10 Africa Benign Prostatic Hyperplasia Devices Market, Overview & Analysis |
10.1 Africa Benign Prostatic Hyperplasia Devices Market Revenues & Volume, 2022-2032 |
10.2 Africa Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By Countries, 2022-2032 |
10.2.1 South Africa Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, 2022-2032 |
10.2.2 Egypt Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, 2022-2032 |
10.2.3 Nigeria Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, 2022-2032 |
10.2.4 Rest of Africa Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, 2022-2032 |
10.3 Africa Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By Procedure Type, 2022-2032 |
10.4 Africa Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By End User, 2022-2032 |
11 Europe Benign Prostatic Hyperplasia Devices Market, Overview & Analysis |
11.1 Europe Benign Prostatic Hyperplasia Devices Market Revenues & Volume, 2022-2032 |
11.2 Europe Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By Countries, 2022-2032 |
11.2.1 United Kingdom Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, 2022-2032 |
11.2.2 Germany Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, 2022-2032 |
11.2.3 France Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, 2022-2032 |
11.2.4 Rest of Europe Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, 2022-2032 |
11.3 Europe Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By Procedure Type, 2022-2032 |
11.4 Europe Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By End User, 2022-2032 |
12 Middle East Benign Prostatic Hyperplasia Devices Market, Overview & Analysis |
12.1 Middle East Benign Prostatic Hyperplasia Devices Market Revenues & Volume, 2022-2032 |
12.2 Middle East Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By Countries, 2022-2032 |
12.2.1 Saudi Arabia Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, 2022-2032 |
12.2.2 UAE Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, 2022-2032 |
12.2.3 Turkey Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, 2022-2032 |
12.3 Middle East Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By Procedure Type, 2022-2032 |
12.4 Middle East Benign Prostatic Hyperplasia Devices Market, Revenues & Volume, By End User, 2022-2032 |
13 Global Benign Prostatic Hyperplasia Devices Market Key Performance Indicators |
14 Global Benign Prostatic Hyperplasia Devices Market - Export/Import By Countries Assessment |
15 Global Benign Prostatic Hyperplasia Devices Market - Opportunity Assessment |
15.1 Global Benign Prostatic Hyperplasia Devices Market Opportunity Assessment, By Countries, 2022 & 2032F |
15.2 Global Benign Prostatic Hyperplasia Devices Market Opportunity Assessment, By Procedure Type, 2022 & 2032F |
15.3 Global Benign Prostatic Hyperplasia Devices Market Opportunity Assessment, By End User, 2022 & 2032F |
16 Global Benign Prostatic Hyperplasia Devices Market - Competitive Landscape |
16.1 Global Benign Prostatic Hyperplasia Devices Market Revenue Share, By Companies, 2025 |
16.2 Global Benign Prostatic Hyperplasia Devices Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here